AU2021368798A1 - Method of treating cancers with alkyne substituted quinazoline derivatives - Google Patents

Method of treating cancers with alkyne substituted quinazoline derivatives Download PDF

Info

Publication number
AU2021368798A1
AU2021368798A1 AU2021368798A AU2021368798A AU2021368798A1 AU 2021368798 A1 AU2021368798 A1 AU 2021368798A1 AU 2021368798 A AU2021368798 A AU 2021368798A AU 2021368798 A AU2021368798 A AU 2021368798A AU 2021368798 A1 AU2021368798 A1 AU 2021368798A1
Authority
AU
Australia
Prior art keywords
compound
egfr
cancer
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021368798A
Other languages
English (en)
Other versions
AU2021368798A9 (en
Inventor
Luca Arista
Elizabeth Buck
David M. Epstein
Alexander Flohr
Tai-An Lin
Matthew Lucas
Matthew O'connor
Giorgio OTTAVIANI
Chris Roberts
Darlene ROMASHKO
Sherri SMITH
Nigel WATERS
Iwona WRONA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Diamond Therapeutics Inc
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of AU2021368798A1 publication Critical patent/AU2021368798A1/en
Publication of AU2021368798A9 publication Critical patent/AU2021368798A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021368798A 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives Pending AU2021368798A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US63/108,645 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US63/166,045 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US63/190,067 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US63/218,717 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US63/237,782 2021-08-27
US202163244540P 2021-09-15 2021-09-15
US63/244,540 2021-09-15
PCT/US2021/057724 WO2022094464A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Publications (2)

Publication Number Publication Date
AU2021368798A1 true AU2021368798A1 (en) 2023-05-18
AU2021368798A9 AU2021368798A9 (en) 2023-07-06

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021368798A Pending AU2021368798A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Country Status (10)

Country Link
US (1) US20240075042A1 (https=)
EP (1) EP4236954A1 (https=)
JP (1) JP2023548055A (https=)
KR (1) KR20230093429A (https=)
AU (1) AU2021368798A1 (https=)
CA (1) CA3195473A1 (https=)
IL (1) IL302329A (https=)
MX (1) MX2023004998A (https=)
TW (1) TWI910256B (https=)
WO (1) WO2022094464A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CA3231697A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122058A2 (en) * 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
JP2022502495A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2020328598A1 (en) * 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
TWI910256B (zh) 2026-01-01
IL302329A (en) 2023-06-01
AU2021368798A9 (en) 2023-07-06
KR20230093429A (ko) 2023-06-27
MX2023004998A (es) 2023-05-12
EP4236954A1 (en) 2023-09-06
WO2022094464A1 (en) 2022-05-05
US20240075042A1 (en) 2024-03-07
CA3195473A1 (en) 2022-05-05
JP2023548055A (ja) 2023-11-15
TW202235083A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
US20240075042A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
US20110033453A1 (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
WO2023140329A1 (ja) がんの治療または予防用医薬
US11395821B2 (en) Treatment of EGFR-driven cancer with fewer side effects
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
AU2015358384B2 (en) Kinase inhibitor prodrug for the treatment of cancer
US9295676B2 (en) Mutation mimicking compounds that bind to the kinase domain of EGFR
CN113164776A (zh) 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2025038731A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
WO2022061299A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
CN116710096A (zh) 用炔取代的喹唑啉衍生物治疗癌症的方法
WO2025090812A1 (en) Methods of modulating cell proliferation
KR20260053328A (ko) 알킨 치환된 퀴나졸린 유도체를 이용한 암 치료 방법
WO2026064728A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
EP4534085A1 (en) Compounds for use in methods of treating cancer
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease
AU2021359826A1 (en) Dosing regimens for cyclin‑dependent kinase 7 (cdk7) inhibitors
CN118791477A (zh) Aak1抑制剂及其用途

Legal Events

Date Code Title Description
SREP Specification republished
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BUCK, ELIZABETH; O'CONNOR, MATTHEW; ROMASHKO, DARLENE; LIN, TAI-AN; FLOHR, ALEXANDER; ARISTA, LUCA; WRONA, IWONA; LUCAS, MATTHEW; ROBERTS, CHRIS; OTTAVIANI, GIORGIO; SMITH, SHERRI; WATERS, NIGEL AND EPSTEIN, DAVID M.